Dr Reddys Laboratories (RDY) Accounts Payables (2012 - 2026)

Dr Reddys Laboratories' Accounts Payables history runs 15 years deep, the most recent figure standing at $365.5 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 10.9% year-over-year to $365.5 million; the TTM figure through Mar 2026 stood at $365.5 million (down 10.9% YoY), while the FY2026 annual figure was $356.0 million, down 14.63% from the prior year.
• Accounts Payables was $365.5 million for Q1 2026 at Dr Reddys Laboratories, up from $101.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $410.2 million in Q1 2025 to a low of -$29.6 million in Q3 2022.
• Historically, Accounts Payables has averaged $202.0 million across 5 years, with a median of $211.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables plunged 144.38% in 2022, then soared 287.0% in 2023.
• A 5-year view of Accounts Payables shows it stood at -$29.6 million in 2022, then jumped by 287.0% to $55.3 million in 2023, then declined by 12.24% to $48.5 million in 2024, then jumped by 109.12% to $101.4 million in 2025, then soared by 260.38% to $365.5 million in 2026.
• The last three Accounts Payables figures came in at $365.5 million (Q1 2026), $101.4 million (Q3 2025), and $72.5 million (Q2 2025), per Business Quant data.